Berliner Tageszeitung - ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium

NYSE - LSE

NGG	-0.27%	58.86	$
SCS	0.68%	11.73	$
RELX	0.65%	45.89	$
VOD	0.71%	8.43	$
AZN	-0.5%	66.3	$
RIO	-0.05%	59.2	$
GSK	-0.09%	34.03	$
RYCEF	-0.14%	7.24	$
RBGPF	100%	59.8	$
CMSC	-0.56%	23.77	$
BTI	0.11%	36.26	$
BCC	0.77%	123.19	$
BCE	0.26%	22.9	$
BP	0.14%	28.79	$
CMSD	0.42%	23.65	$
JRI	0.41%	12.15	$

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium

ECONOMY 06.12.2024

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium

ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium.

Text size:

PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer.

ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on these findings as well as earlier in vivo efficacy studies, ProteinQure has initiated GLP-toxicology studies for PQ203 in support of an anticipated investigational new drug application filing in Q2 of 2025.

"These combined findings confirm the power of our computational drug design platform and its potential to address key challenges in cancer therapy. We are deeply committed to moving PQ203 forward and are eager to bring this innovative treatment to clinical trials." stated Lucas Siow, CEO of ProteinQure.

Phase 1a/b trial initiation for PQ203 is planned for the second half of 2025 and will be coordinated at the Princess Margaret Cancer Center in Toronto and other leading hospitals in North America.

For media inquiries please contact Lucas Siow at [email protected]

SOUCE: ProteinQure Inc.

D. Meier--BTZ

Featured

2004 Indian Ocean tsunami: what to know 20 years on

Survivors and victims' relatives will next week mark the 20th anniversary of the 2004 Indian Ocean earthquake and tsunami, which killed more than 220,000 people across more than a dozen countries.

Russian state owner says cargo ship blast was 'terrorist attack'

A "terrorist act" sank the cargo ship that went down in international waters in the Mediterranean this week, the Russian state-owned company that owns the vessel said Wednesday.

Sweeping Vietnam internet law comes into force

New Vietnamese internet rules requiring Facebook and TikTok to verify user identities and hand over data to authorities came into force on Wednesday, in what critics say is the latest attack on freedom of expression.

Thousands attend Christmas charity dinner in Buenos Aires

Some 3,000 homeless people sat down for a festive Christmas charity dinner on Tuesday in the center of Buenos Aires, at a time when more than half of Argentina's population is affected by poverty, one year into ultra-liberal Javier Milei's term in office.